Search results
John Cleese says he’s been spending £17,000 annually on stem cell therapy to ‘buy a few extra years’
The Independent via Yahoo News· 7 hours agoJohn Cleese has revealed he has been spending £17,000 every 12 months for the past 20 years on stem...
Intra-Cellular Therapies (NASDAQ:ITCI) Given New $107.00 Price Target at Canaccord Genuity Group
ETF DAILY NEWS· 10 hours agoIntra-Cellular Therapies (NASDAQ:ITCI – Free Report) had its target price increased by Canaccord Genuity Group from $100.00 to $107.00 in a research note published on Tuesday ...
How psychedelic-assisted therapies can be more effective
Popular Science via Yahoo News· 21 hours agoThe clinician provides hours or preparation and also guides the patient through the experience and...
Taysha Gene Therapies Inc (TSHA) Shares Rise Despite Market Challenges – News Heater
NewsHeater· 8 hours agoTaysha Gene Therapies Inc (NASDAQ: TSHA) has seen a rise in its stock price by 2.85 in relation to its previous close of 2.46. Is It Worth Investing in Taysha Gene Therapies Inc (NASDAQ: TSHA ...
America’s health system is still in crisis after its biggest cyberattack ever—but the ‘catastrophe’...
Fortune via Yahoo Finance· 22 hours agoIn early March, Joe Martin, the owner of Function Better, a physical therapy clinic in Yorkville,...
Male infertility contributes to about 40% of cases of infertility. What to do about it
CNN.com· 39 minutes agoEditor’s note: Dr. Jamin Brahmbhatt is a urologist and robotic surgeon with Orlando Health and an...
'Our students can't wait': how a new law will help kids access consistent therapy at school
Green Bay Press-Gazette via Yahoo News· 5 hours agoIt’s an effort many have been pushing for since Wisconsin recognized the profession more than 50...
Intra-Cellular Therapies (NASDAQ:ITCI) PT Raised to $91.00 at Bank of America
ETF DAILY NEWS· 5 days agoIntra-Cellular Therapies (NASDAQ:ITCI – Get Free Report) had its target price upped by stock analysts at Bank of America from $82.00 to $91.00 in a research note issued on ...
Intra-Cellular Therapies (NASDAQ:ITCI) Given New $96.00 Price Target at Mizuho
ETF DAILY NEWS· 1 day agoThe Goldman Sachs Group upped their target price on shares of Intra-Cellular Therapies from $67.00 to $77.00 and gave the stock a neutral rating in a research note on Wednesday ...
Side effects of 'magic mushrooms' are similar to regular antidepressants
UPI· 21 minutes agoPeople in a new study who took psilocybin often experienced headache, nausea, anxiety, dizziness and...